Treatment of Helicobacter pylori infection

Area of Science:

• Gastroenterology
• Infectious Diseases
• Microbiology

Background:

• Current Helicobacter pylori eradication rates are suboptimal, around 80%, with lower success in patients who have not responded to initial treatment.
• Increasing antibiotic resistance, particularly in Southern Europe, and expanded indications for H. pylori treatment necessitate more effective eradication strategies.
• Factors like smoking and short treatment durations predict eradication failure, especially in functional dyspepsia patients.

Purpose of the Study:

• To review and highlight the need for improved Helicobacter pylori eradication strategies.
• To discuss current treatment limitations and emerging challenges.
• To provide recommendations for optimizing eradication success in clinical practice.

Main Methods:

• Review of current clinical practice guidelines and relevant literature on Helicobacter pylori eradication.
• Analysis of factors influencing treatment success and failure.
• Evaluation of first-line and second-line treatment options.

Main Results:

• Clarithromycin-based regimens remain the preferred first-line option, but extended treatment duration is now advised.
• For patients with first-line treatment failure, 14-day proton pump inhibitor triple therapy with alternative antibiotics or quadruple therapy are viable options.
• Levofloxacin-based 10-day triple therapy shows promise as an effective strategy after one or more prior eradication failures.

Conclusions:

• Optimizing Helicobacter pylori eradication requires adapting treatment durations and employing alternative antibiotic regimens.
• Addressing antibiotic resistance and patient-specific factors is key to improving treatment outcomes.
• Levofloxacin-based therapies represent a promising approach for refractory H. pylori infections.